Publications

Dieter SM, Siegl C, Codo P, Huerta M, Ostermann-Parucha A, Schulz E, Zowada MK, Martin S, Laaber K, Nowrouzi A, Blatter M, Kreth S, Westermann F, Benner A, Uhrig U, Putzker K, Lewis J, Haegebarth A, Mumberg D, Holton, SJ, Weiske J, Toepper LM, Scheib U, Siemeister G, Ball CR, Kuster B, Stoehr G, Hahne H, Johannes S, Lange M, Herbst F, Glimm H. Degradation of Cyclin K/CDK12 is a druggable vulnerability of colorectal cancer.  Cell Reports, 2021 Jul 20;36(3):109394

Herbst F, Lang T, Eckert ESP, Wünsche P, Kindinger T, Laaber K, Hemmati S, Hotz-Wagenblatt A, Zavidij O, Paruzynski A, Lu J, von Kalle C, Zenz T, Klein C, Schmidt M, Ball CR, Glimm H. The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision. Leukemia, 2021 Oct;35(10):2948-2963

Hanf D, Heining C, Laaber K, Nebelung H, Uhrig S, Hutter B, Jahn A, Richter D, Aust D, Herbst F, Fröhling S*, Glimm H*, Folprecht G*. Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation.  JCO Precis Oncol, 2021 Apr 22;5: PO.20.00278

Wünsche P, Eckert ESP, Holland-Letz T, Paruzynski A, Hotz-Wagenblatt A, Fronza R, Rath T, Gil-Farina I, Schmidt M, von Kalle C, Klein C, Ball CR, Herbst F*, Glimm H*. Mapping active gene-regulatory regions in human repopulating long-term HSCs. Cell Stem Cell, 2018 Jul 5;23(1):132-146